AstraZeneca representatives gave presentations on oncology research at the 2015 European Cancer Congress (ECC) in Vienna.

K2M Group Holdings Inc. has commercially launched its spinal technology.

Biogen and Swedish Orphan Biovitrum AB (Sobi) have received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to market Elocta.

Limits on patient eligibility are making it difficult for some primary care physicians to switch over from private insurance to direct primary care (DPC) practice models.

A recent health proposal by Democratic presidential candidate Hillary Clinton is facing by the Biotechnology Industry Organization, which said it would do more harm than good to Americans.

Government agencies and private payers are being lobbied by the AAFP, who wants to make sure that patients with diabetes have access to the medical supplies they need.

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Global pharmaceutical company AbbVie's Viekirax, a treatment for adult patients living with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. Japan has one of the highest rates of hepatitis C infection in the industrialized world, with an estimated 1.5 to 2 million people living with the disease.

Bayer HealthCare said it has received approval from the U.S. Food and Drug Administration for Betaconnect, the first-of-its-kind electronic autoinjector indicated for the treatment of relapsing-remitting multiple sclerosis. The product is expected to be available in early 2016 to patients who take Betaseron (interferon beta-1b). Betaseron is used to decrease the number of relapses in MS patients.

The U.S. Food and Drug Administration (FDA) granted approval for Aristada (aripiprazole lauroxil), an extended-release injection, for the treatment of adults with schizophrenia on Monday. Aristada, a product of Dublin, Ireland-based biopharmaceutical company Alkermes, is administered by a health care professional every four to six weeks by injection in the arm or buttocks.

A recent study conducted by the Government Accountability Office (GAO) found that the federal government's program mandating that doctors and hospitals maintain electronic health records for patients actually might be impeding the exchange of data between electronic health records systems.

Lonsurf is an oral medication used to treat advanced colorectal cancer.

True Human therapeutic antibody therapy being developed to treat all forms of staph infections.

Boehringer Ingelheim and BioMed X have teamed up to develop a crowdsourcing approach to put together a research team; the team, made up of scientists from around the globe, will work toward finding new ways to treat patients suffering from chronic obstructive pulmonary disease (COPD), which is a chronic, progressive and treatable -- but incurable -- lung disease, which currently affects nearly 210 million people around the world.

Rosetta Genomics Ltd. of Princeton, New Jersey, a developer and provider of microRNA-based and other molecular diagnostics, recently received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/446,505, titled “Compositions and Methods for the Prognosis and Treatment of Prostate Cancer,” a patent that is designed to provide an effective prostate cancer treatment. 

A clinical stage biopharmaceutical company, Cellectar Biosciences Inc., recently received initial notice of an award for a Phase I-II Fast-Track Small Business Innovation Research (SBIR) grant issued for one of its cancer treatment drugs; the grant is for up to $2.3 million from the National Cancer Institute (NCI), which will be used to fund development of Cellectar's PDC platform for targeted delivery of I-125, a radiotherapeutic isotope that may be effective against micro-metastatic disease.

Eli Lilly and Co. and Incyte Corp. have announced the achievement of positive top-line results of RA-BEGIN, the Phase 3 study for baricitinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA); test subjects for the RA-BEGIN study had limited or no prior treatment with methotrexate, and they had no knowledge of other conventional or biologic disease-modifying anti-rheumatic drugs (DMARDs). 

A Boston Medical Center (BMC) program that incorporates addiction treatment into primary care for patients who either have or are at risk of contracting HIV was recently proven to decrease patients' dependence upon substances and increase the odds that they might seek treatment; findings gleaned from the program were published online in the Journal of Substance Abuse Treatment.

BodyA Canadian research team under the leadership of Dr. Mark Ware of the Research Institute of the McGill University Health Centre (RI-MUHC) in Montréal, Canada recently completed a national multi-center study on the safety of medical cannabis use among patients with chronic pain.

A recent study by the NYU Langone Medical Center indicated that an experimental drug the National Cancer Institute library of chemical compounds originally found to be a potential brain and basal-cell cancer treatment actually reduced the symptoms of mice afflicted with a form of multiple sclerosis.

Eagle Pharmaceuticals has been granted a U.S. patent for its bendamustine hydrochloride (HCl) formulation administered in a 50 mL bag within 10 minutes. The product is indicated for use in patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.